drugset
drugset / Trial / NCT01366820

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC

NCT01366820 ↗

Phase 2 Completed 261 enrolled Neuren Pharmaceuticals Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).

Timeline

Start
2013-02
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Trofinetide Peptide 6 mg/kg Intravenous

Indications

brain injury